
On Nov. 9, 2026, the FDA ordered a new eye warning on every GLP-1 drug — Ozempic, Wegovy, Mounjaro, Zepbound, and eight others. The warning covers NAION, a rare “eye stroke” that can cause sudden, painless, permanent vision loss in one eye. Below: exactly how big the real risk is, who’s most likely to be affected, what the ongoing lawsuits do and don’t prove, and the warning signs that mean you should call a doctor today. Do not stop your medicine on your own.
- In this guide: the exact FDA numbers explained in plain English
- Who faces higher risk, and why diabetes changes the math
- What the Ozempic/Zepbound lawsuits actually allege — and what they don’t prove
What Is NAION, the “Eye Stroke” Behind This Warning?
NAION (non-arteritic anterior ischemic optic neuropathy) happens when blood flow to the optic nerve drops and part of the nerve is starved of oxygen. It’s sometimes nicknamed a “stroke of the optic nerve.” It almost always affects one eye, and it typically does not cause total blindness — most people lose a section of their visual field (often the upper or lower half) rather than all sight in that eye.
According to the FDA, the symptoms to watch for are:
- Sudden, painless vision loss in one eye — often first noticed on waking up
- Blurred or missing portions of vision, like blind spots or tunnel vision
- Distorted or washed-out colors
- Reduced sharpness in the center of your vision
NAION Incidence Across Studies
Cases per 100,000 person-years
| Category | NAION cases per 100,000 person-years |
|---|---|
| General pop. 50+ | 6.25 |
| FDA trial: comparator | 3.8 |
| FDA trial: GLP-1 | 6.4 |
| Sentinel: DPP-4 | 26 |
| Sentinel: SGLT-2 | 31 |
| Sentinel: GLP-1 | 31 |
What the FDA Announced on Nov. 9, 2026
The FDA's drug safety communication requires every GLP-1 receptor agonist on the market to add NAION to the Warnings and Precautions section of its label. That's a longer list than most coverage mentions:
| Brand name | Generic name |
|---|---|
| Ozempic, Rybelsus | semaglutide |
| Wegovy | semaglutide |
| Mounjaro, Zepbound | tirzepatide |
| Victoza, Saxenda | liraglutide |
| Trulicity | dulaglutide |
| Xultophy | liraglutide + insulin degludec |
| Soliqua | lixisenatide + insulin glargine |
| Foundayo | orforglipron (the new pill, approved 2026) |
| Byetta | exenatide (brand discontinued; generics still sold) |
The FDA calls this a potential increased risk, not proven cause and effect — it found no biological mechanism in animal studies. A Lilly spokesperson said the notice "does not reference any findings specific to Lilly medicines." Novo Nordisk says it has not seen a safety signal in its own randomized trials.
How Big Is the Real Risk?
| Source | What it found |
|---|---|
| FDA trial meta-analysis (126 trials, 134,253 patients) | 6.4 NAION cases per 100,000 person-years on GLP-1 drugs vs. 3.8 on placebo/other diabetes drugs |
| FDA Sentinel real-world study (type 2 diabetes only) | 43% higher risk vs. DPP-4 inhibitors; no statistically significant difference vs. SGLT-2 inhibitors |
| European Medicines Agency (semaglutide) | "Very rare": up to 1 in 10,000 users |
| Background risk, general population 50+ | 2.3 to 10.2 cases per 100,000 people per year |
Translating the trial numbers: the gap between 6.4 and 3.8 works out to roughly one additional NAION case for every 38,500 person-years of GLP-1 use — and that estimate is built on just 10 observed cases, so the true number could be meaningfully higher or lower. The FDA's separate real-world study, which only looked at people with type 2 diabetes, found much higher baseline rates across the board (26–32 cases per 100,000 person-years) because diabetes itself is a major NAION risk factor. Within that group, GLP-1 drugs looked riskier than DPP-4 inhibitors but not riskier than SGLT-2 inhibitors — a sign the picture still depends heavily on what you compare against.
In plain terms: most users will never have this problem. Still, because NAION can be permanent, it deserves attention.
Timeline: How We Got Here
- July 2024: A Mass Eye and Ear study in JAMA Ophthalmology (Hathaway et al.) first linked semaglutide to higher NAION rates. The FDA later said it identified limitations in this study but found them significant enough to warrant further review.
- 2025: The European Medicines Agency called NAION a very rare semaglutide side effect; the WHO issued a matching alert; Danish regulators compensated several affected patients.
- Feb. 2026: The UK's MHRA updated semaglutide product information.
- June 2026: A systematic review from the American Academy of Ophthalmology reported no evidence of a consistent overall increase in NAION risk.
- Aug. 2026: A joint statement from the AAO and the North American Neuro-Ophthalmology Society said the overall magnitude of NAION risk "remains low."
- Nov. 9, 2026: The FDA ordered class-wide U.S. label changes.
Ozempic vs. Zepbound: Is the Risk the Same?
Most of the research so far is on semaglutide (Ozempic, Wegovy), simply because it's been on the market longer. Tirzepatide (Mounjaro, Zepbound) has far less published NAION data — but the FDA applied the same warning to it, based on cases reported across the whole drug class, not just one product. Lilly has said it monitors the research and would update labeling if a clear tirzepatide-specific signal emerged. Treat the Zepbound/Mounjaro risk as possible and still largely unproven, not settled in either direction.
Who's Most at Risk? Known Risk Factors
NAION's underlying cause isn't fully understood, with or without GLP-1 use. But both the FDA and eye specialists point to overlapping risk factors — many of which are the same conditions GLP-1 drugs are prescribed to treat:
- Age 50 or older
- Type 2 diabetes (a different issue from diabetic retinopathy, below)
- Smoking
- High blood pressure or high cholesterol
- Sleep apnea
- Anemia or kidney disease
- Being male (men develop NAION more often than women)
What Happens If You Develop NAION?
There's no approved treatment for NAION itself. Doctors instead focus on ruling out other causes and managing the underlying risk factors — blood pressure, blood sugar, sleep apnea — that may have contributed. Because the condition is uncommon, long-term outcome data is limited, but ophthalmology estimates suggest about 70% of patients see no further change after onset, roughly 20% see some improvement, and about 10% get worse. Around 15% of people who develop NAION in one eye eventually develop it in the other, which is why ongoing eye and health monitoring matters even after a first episode.
"The most important thing is to put the risk into perspective."
Chintan Dave, PharmD, PhD, Rutgers Institute for Health
A Second, More Common Eye Risk: Diabetic Retinopathy
If you have type 2 diabetes, there's a separate and more familiar concern. In the trial behind Ozempic's label, rapid blood sugar improvement was linked to temporary worsening of diabetic retinopathy — complications occurred in 3.0% of Ozempic users vs. 1.8% on placebo, mostly in patients who already had retinopathy. Zepbound's label carries a similar caution. Doctors call this "early worsening," and it's generally temporary, unlike NAION.
Warning Signs: Act the Same Day
- Sudden, painless vision loss in one eye
- Vision loss you first notice after waking up
- Blurry or missing areas in your vision
- Washed-out colors or less sharp central vision
The Lawsuits: What's Actually Being Claimed
The FDA's warning follows a wave of litigation. By late 2026, more than 90 personal-injury lawsuits had been filed against Novo Nordisk in New Jersey state court, and separate plaintiff firms say they represent upward of 150 people who developed NAION after taking various GLP-1 drugs for diabetes or weight loss. The suits allege the companies didn't adequately warn patients. Novo Nordisk has called the claims without merit and says it's defending them; Eli Lilly says it continues to review the available safety data.
It's worth being clear about what a lawsuit does and doesn't show: a legal claim is an allegation, not a scientific finding. That's part of why the FDA's own language stays cautious — "potential increased risk," not a confirmed cause.
10 Facts to Know
- The warning covers 12 drugs, not just Ozempic and Zepbound — including the new pill Foundayo (orforglipron).
- NAION rarely causes total blindness; most patients keep part of their vision in the affected eye.
- The FDA's trial data points to roughly one extra case per 38,500 person-years of use — based on just 10 observed cases, so treat it as a rough estimate.
- In FDA's real-world diabetes study, GLP-1 drugs looked riskier than one comparator drug class but not another.
- About 15% of people who get NAION in one eye eventually get it in the other.
- Men develop NAION more often than women.
- More than 90 lawsuits have been filed against Novo Nordisk alone — but lawsuits are allegations, not proof of cause.
- A joint 2026 statement from two major ophthalmology groups said overall NAION risk "remains low."
- The FDA found no biological mechanism in animal studies, so how (or if) these drugs cause NAION is still unknown.
- Rapid blood-sugar drops can separately cause temporary diabetic retinopathy worsening — a different, usually reversible problem.
What You Should Do
- Keep your next appointment. Ask your prescriber how this warning applies to you.
- Do not quit on your own. These drugs also lower heart and blood sugar risks; your doctor will weigh both sides.
- Know the stop rule. If NAION is confirmed, doctors are advised to consider stopping the drug unless the benefits clearly outweigh the risk.
- Take extra care after a past NAION. There's a higher chance of a repeat event, including in the other eye.
- Get regular eye exams, especially with diabetes, high blood pressure, high cholesterol, or sleep apnea.
- Report side effects to FDA MedWatch.
FAQ
Does Ozempic cause blindness? Regulators call NAION a rare, possible side effect that can cause permanent but usually partial vision loss in one eye. A direct cause-and-effect link has not been proven.
Is Zepbound safer for eyes than Ozempic? No one can say yet — tirzepatide has far less NAION research than semaglutide, and the FDA warning covers both equally.
Are there lawsuits against Ozempic for vision loss? Yes — more than 90 suits against Novo Nordisk alone, plus claims against other manufacturers. The companies dispute the claims, and lawsuits don't establish medical causation on their own.
Should I stop my shot today? No. Call your doctor with questions, and get urgent care if your vision changes suddenly.
Medical disclaimer: This article is for education only. It is not medical advice. Talk to your doctor before you change any medicine.





